All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

Biodegradable Guar Gum Nanoparticles as Carrier for Tamoxifen Citrate in Treatment of Breast Cancer

Comparison of Clomiphene Citrate Plus Estradiol, with Tamoxifen Citrate Effects in Induction of Ovulation and Pregnancy in Poly Cystic Ovarian Syndrome Patients

Inhibitory effects of Indigofera aspalathoides on 20-methylcholanthrene-induced chemical carcinogenesis in rats

Preparation and in vitro characterization of poly (epsilon-caprolactone)-based tamoxifen citrate-loaded cylindrical subdermal implant for breast cancer

Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation

Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation

Preparation and in vitro characterization of the transdermal drug delivery system containing tamoxifen citrate for breast cancer

IN-VITRO CYTOTOXICITY ANALYSIS OF TAMOXIFEN CITRATE LOADED CROSS-LINKED GUAR GUM NANOPARTICLES ON JURKAT (HUMAN T-CELL LEUKEMIA) CELL LINE

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness

More...

Effect of administration of tamoxifen citrate on xanthine oxidase activity of liver during 3-methylcholanthrene induced carcinogenesis in female albino mice

Keywords: Tamoxifen citrate , xanthine oxidase , drug metabolism , carcinogenesis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Tamoxifen citrate, the non-steroidal anti-estrogen and the first selective estrogen receptor modulator is the treatment of choice for patients with all stages of estrogen receptor positive breast cancer. Although Cytochrome P-450s (CYP) are well known to be responsible for much of its metabolism, fragmentary studies have been carried out to analyze the activity of xanthine oxidase, a non-CYP drug metabolizing enzyme, in tamoxifen metabolism. So, the present investigation is aimed to ascertain the effect of tablet and nano-formulation of tamoxifen on xanthine oxidase expression during 3-methylcholanthrene-induced carcinogenesis. It is found that oral administration of tamoxifen in both the formulations significantly (p < 0.01) decreases the xanthine oxidaseactivity in liver tissue of female mice. We speculate our results to be beneficial for the better understanding of drug metabolism and intensity, which in turn will pave the way for new and efficient nano-formulations of drug coming into therapeutic use.

Full-Text

comments powered by Disqus